FT. LAUDERDALE, FL -- January 25, 2023 -- InvestorsHub
NewsWire -- Kaya Holdings, Inc., ("KAYS" or the "Company")
KAYS), a pioneer in the U.S. cannabis industry, announced today
that it has launched Fifth Dimension Therapeutics™ (“FDT”), which
will seek to provide psychedelic “mind care” treatments to veterans
suffering from PTSD, addicts seeking to break addiction,
individuals with eating disorders, and others with a wide array of
treatment resistant mental health disorders.
It is estimated that approximately every 40 seconds
someone in the world commits suicide.
Psilocybin may soon be available as a mainstream
medical treatment for treatment resistant depression (TRD) and
other mental health diseases, potentially providing a new lease on
life for millions worldwide for whom current medications do not
The Company is pleased to announce that one of its senior
employees, Bryan Arnold, has been enrolled in one of the first
training courses to qualify for an Oregon Psilocybin Facilitator
License, permitting him to oversee the cultivation of psilocybin
mushrooms and related products as well as operate up to five (5)
state licensed facilitation clinics where psilocybin treatments
will be administered. Bryan is expected to complete his training
and apply for licensure in April.
Additionally, the Company is proud to welcome attorney Glenn
E.J. Murphy to the FDT Board of Director. Glenn will assist FDT
with introductions to pharmaceutic companies seeking data and
access to psychedelic patients, as well as advising on the
development of intellectual property, structure of potential joint
ventures, funding opportunities, acquisitions, and other related
“The operation of a psychedelics treatment enterprise has many
parallels to the cannabis industry, and we feel that KAYS is among
the companies uniquely qualified to deliver the highest quality of
care to the patients wishing to avail themselves of these promising
new treatments”, stated W. David Jones, a KAYS Senior Advisor and
driving force behind the Company’s entry into the psychedelics
arena. “We believe we can help provide meaningful benefits to the
millions suffering from treatment resistant mental health
conditions while significantly enhancing shareholder value.”
“We have effectively shifted our cannabis operations toward the
European market where we believe a substantial market exists
without the same regulatory burdens of the fragmented and
nationally stymied U.S market”, adds KAYS’ CEO Craig Frank. “By
bringing all we have learned from our cannabis operations to the
psychedelics market, I believe we have an excellent opportunity to
secure a leadership role in the ‘mind care’ market”.
Mental health disorders account for several of the top causes of
disability in the United States. A 2021 Harvard University study
forecasted the annual medical cost of mental health conditions to
reach $6 trillion by 2030.
It is estimated by the National Institute of Mental Health
Disorders that 26% of Americans over 18 years of age suffer from a
diagnosable form of depression (major or clinical depression, manic
or bipolar depression), and an additional 40 million American
adults suffer from an anxiety disorder (panic disorder,
obsessive-compulsive disorder (OCD), post-traumatic stress disorder
(PTSD), generalized anxiety disorder (GAD), and social phobia,
agoraphobia, and specific phobias). Depressive illnesses tend to
co-occur with substance abuse and anxiety disorders
In 2021, Data Bridge Market Research estimated the current U.S.
psychedelics market value to be $2.8 billion, with a forecasted
2029 market expected to reach $8.9 billion.
The growing evidence suggests that psychedelics act on the
brain’s default network, or those regions of the brain that remain
active when your brain is not engaged in active tasks. Psilocybin
increases activity in certain neurons that respond to the
neurotransmitter serotonin, which has wide- ranging functions in
the human brain (many of which are being researched). Ketamine is
most active in the glutamate system.
The default network provides a “framework” for the brain’s
activity, providing structure and making order of all that is
happening in the cortex and keeping external neurological
information (delivered via our senses) distinct from internally
generated activity thoughts, emotions, and memory).
Psychedelics seem to suppress the default network, relaxing the
separation of our senses, memories, thoughts, and emotions, and
enabling each to influence each other more easily. This ability to
break down of the brain’s “framework” has led to a focus on
psychedelics as a groundbreaking opportunity to address a wide
range of mental health disorders.
Glenn Murphy’s Biography
Glenn has twenty-five years of private and corporate practice,
including ten years in-house with the Henkel Group and more than
fifteen years in private practice, Glenn’s experience has touched
on most every aspect of intellectual property practice.
Glenn’s current practice primarily focuses on building and
managing domestic and international utility and design patent
portfolios and opining on the validity and infringement of U.S.
patents. In addition to drafting and prosecuting patent
applications filed in the U.S. and foreign patent offices, Glenn
has briefed and argued before the U.S. Patent Office Board of
Appeals, assisted with the preparation and argument of appeals
before the U.S. Court of Appeals for the Federal Circuit, and
assisted with the conduct of bench and jury trials in the U.S.
District Courts and the U.S. International Trade Commission. He has
provided due diligence and advice in acquisitions, divestments,
licenses, and other transactions involving intellectual property
rights. He has particular experience in building and managing
domestic utility and design patent portfolios for non-U.S.
After receiving his B.S. in chemical engineering in 1984 from
the Pennsylvania State University, Mr. Murphy worked as an engineer
for the Cochrane Division of Crane Company, designing and
delivering large-scale water treatment systems for industry. In
1990 he received his J.D. with honors from the University of
Pittsburgh School of Law, where he served as an editor of the
school’s Journal of Law and Commerce and received the Faculty Award
for Excellence in Legal Scholarship.
Mr. Murphy is a member of Ratner Prestia’s Biotechnology,
General Chemistry and Polymers and Pharmaceutical Chemistry Groups.
To review Mr. Murphy’s biography, please go to https://www.ratnerprestia.com/professionals/glenn-e-j-murphy/
KAYS SHAREHOLDERS AND OTHER INTERESTED PARTIES - PLEASE
UPDATE YOUR CONTACT INFORMATION
We routinely receive calls and emails from shareholders asking
us questions about KAYS, so we are asking all KAYS shareholders to
email us and confirm their contact info. Please email
firstname.lastname@example.org with "KAYS shareholder update" in the subject
line and include your name, address, phone number and number of
shares you own so that we may make sure you receive all updates and
can respond to any shareholder inquiries.
About Kaya Holdings, Inc.
Kaya Holdings, Inc. (OTCQB:KAYS)
is a Mind Care Company with longstanding operations as a
touch-the-plant, vertically integrated legal cannabis business
operating a number of majority-owned subsidiaries to retail,
cultivate, produce and distribute premium medical and recreational
cannabis products. The Company is evolving into a full mind care
enterprise with the planned introduction psilocybin at-home and
in-facility treatments, as permitted by law. KAYS is a fully
reporting, US-based publicly traded company, listed for trading on
the OTCQB Tier of the over-the-counter market under the symbol
Summary of Operations
KAYS corporate structure includes the following four
majority-owned subsidiaries, each responding to various demands and
opportunities in the cannabis or psychedelic industry:
Fifth Dimension Therapeutics, Inc., serves as
the Company’s operating branch to the psychedelic treatment sector,
including operation of mushroom cultivation facilities, in-facility
treatment centers, and at-home treatment programs.
Marijuana Holdings Americas, Inc. owns the Kaya
Shack™ brand of licensed medical and recreational marijuana stores
(www.kayashack.com) and the Kaya Farms™ brand of
cannabis production and processing operations that operate in the
Kaya Brands International, Inc., serves as the
vehicle for the Company's non-U.S. operations including cultivation
activities in Greece and Israel.
Kaya Brands USA, Inc. owns a wide range of
proprietary brands of cannabis extracts, oils, pre-rolls, topicals,
edibles and beverages, cannaceuticals and related accessories.
KAYS is planning execution of its stated business objectives in
accordance with current understanding of state and local laws and
federal enforcement policies and priorities as it relates to
cannabis and psychedelics. Potential investors and shareholders are
cautioned that KAYS and subsidiaries including FTD will obtain
advice of counsel prior to actualizing any portion of their
business plan (including but not limited to license applications
for the cultivation, distribution or sale of marijuana and
psychedelic products, engaging in said activities or acquiring
existing production/sales operations). Advice of counsel with
regard to specific activities of KAYS, federal, state or local
legal action or changes in federal government policy and/or state
and local laws may adversely affect business operations and
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "project," "expect" or similar statements
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such
differences include, but are not limited to, acceptance of the
Company's current and future products and services in the
marketplace, the ability of the Company to develop effective new
products and receive regulatory approvals of such products,
competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this
For more information contact Investor Relations: email@example.com or 561-400-1971.
Kaya (QB) (USOTC:KAYS)
Historical Stock Chart
From Feb 2023 to Mar 2023
Kaya (QB) (USOTC:KAYS)
Historical Stock Chart
From Mar 2022 to Mar 2023